Bamco Inc. NY Trims Stock Position in Veeva Systems Inc. $VEEV

Bamco Inc. NY trimmed its holdings in Veeva Systems Inc. (NYSE:VEEV) by 2.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 358,291 shares of the technology company’s stock after selling 9,889 shares during the period. Bamco Inc. NY owned 0.22% of Veeva Systems worth $103,181,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Sigma Planning Corp boosted its position in shares of Veeva Systems by 1.2% in the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock worth $958,000 after acquiring an additional 39 shares during the last quarter. Keybank National Association OH raised its stake in Veeva Systems by 1.4% during the second quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock worth $889,000 after purchasing an additional 42 shares during the period. Facet Wealth Inc. boosted its holdings in shares of Veeva Systems by 3.3% in the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock valued at $381,000 after purchasing an additional 43 shares during the last quarter. TFB Advisors LLC grew its stake in shares of Veeva Systems by 1.2% during the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock valued at $831,000 after buying an additional 44 shares during the period. Finally, Triangle Securities Wealth Management grew its stake in shares of Veeva Systems by 0.8% during the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock valued at $1,665,000 after buying an additional 45 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Insider Activity

In related news, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. This represents a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jonathan Faddis sold 720 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $298.12, for a total value of $214,646.40. Following the transaction, the senior vice president owned 7,868 shares in the company, valued at $2,345,608.16. This trade represents a 8.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is currently owned by insiders.

Veeva Systems Stock Performance

Shares of Veeva Systems stock opened at $222.87 on Friday. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The firm’s 50-day simple moving average is $273.45 and its 200-day simple moving average is $278.41. The firm has a market cap of $36.63 billion, a PE ratio of 43.36, a price-to-earnings-growth ratio of 1.71 and a beta of 1.05.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.09. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The firm had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. During the same period in the previous year, the company earned $1.75 earnings per share. Veeva Systems’s quarterly revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, equities analysts predict that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Analysts Set New Price Targets

VEEV has been the topic of a number of research analyst reports. Morgan Stanley lifted their target price on Veeva Systems from $210.00 to $222.00 and gave the company an “underweight” rating in a report on Thursday, August 28th. Piper Sandler raised their price objective on Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a report on Thursday, August 28th. Oppenheimer reaffirmed an “outperform” rating and issued a $325.00 price objective on shares of Veeva Systems in a research note on Thursday, August 28th. Citigroup dropped their target price on shares of Veeva Systems from $349.00 to $319.00 and set a “buy” rating for the company in a research report on Monday, November 24th. Finally, KeyCorp restated a “sector weight” rating on shares of Veeva Systems in a report on Friday. Eighteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $307.42.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.